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Abstract
Background: We have previously reported a novel constitutively overexpressed 21 kDa protein in Hodgkin
Lymphoma (HL) and aggressive Non-Hodgkin Lymphomas (NHL). The objective of the current study was to 1)
identify this protein using two independent methods, 2) study the expression of the protein and its encoding
mRNA in reactive lymph nodes, normal lymphocytes and CD34+ bone marrow precursor cells, 3) analyse patterns
of expression of the protein in tissue microarrays assembled from a large number of diagnostic clinical biopsies
from patients with HL, and 4) determine the copy number variation and mutation status of the encoding gene in
HL cell lines.
Results: Peptide sequencing by LC-MS/MS and protein identification by protein array screening identified a single
protein, CYB5B. No mutations were detected in the CYB5B gene in HL cell lines. Quantitative PCR showed CYB5B
gene expression was increased in HL and NHL cell lines. Array CGH using a submegabase resolution tiling array
revealed gains in the CYB5B locus in HL cell lines KMH2 and L428. Membrane expression was seen in Reed-
Sternberg cells in clinical biopsies from patients with HL but not in reactive lymph nodes. Bone marrow CD34+
precursor cells were CYB5B negative on the cell surface. RT-PCR assays of RNA extracted from T and B cell enriched
fractions obtained from normal peripheral blood mononuclear cells, reactive lymph nodes, tonsils and normal bone
marrow samples showed no evidence of increased mRNA levels of CYB5B in comparison to housekeeping gene
GAPDH.
Conclusions: The 21 kDa protein overexpressed in HL and aggressive NHL is identical to CYB5B. CYB5B gene
expression is increased in a subset of HL and NHL cell lines tested. This is associated with CYB5B gene amplification
in HL cell lines KMH2 and L428. CYB5B may be a potential target for antibody-based therapy of HL and aggressive
NHL as although cytoplasmic expression is present in reactive lymphocytes, it is not expressed on the cell surface
of non-neoplastic lymphocytes or bone marrow precursor cells.
Background
Human malignant lymphomas are neoplasms arising
from lymphocytes at various stages of differentiation,
and are currently placed into 2 distinct clinical group-
ings, namely Hodgkin Lymphoma (HL) and non-Hodg-
kin Lymphoma (NHL), although, as discussed below, the
major groups overlap considerably in terms of cellular
origins. NHL is a heterogeneous group of malignant
lymphomas comprising over 60 different clinical sub-
types, the most common being diffuse large B cell lym-
phoma (DLBCL), which is an aggressive form, followed
by follicular lymphoma (FL) which is usually indolent. T
cell lymphomas are generally aggressive but relatively
infrequent [1].
HL is subdivided into nodular lymphocyte predomi-
nance, and classical types which include 4 subtypes:
lymphocyte-rich classical, nodular sclerosis, mixed cellu-
larity and lymphocyte depletion forms [1].
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HL had a worldwide incidence of 62,000 cases in
2002; current global estimates are not readily available.
Compared with North America and Europe, HL is rela-
tively rare in Japan (age-adjusted incidence of 0.3 per
100,000 males) and China (age-adjusted incidence of 0.2
per 100,000 males). In developing countries, the inci-
dence of the mixed-cellularity (MCHD) and lympho-
cyte-depleted (LDHD) subtypes of HL is higher than in
developed countries. In contrast, the nodular-sclerosis
(NSHD) subtype is the most frequent form of HL in
developed countries (GLOBOCAN 2002 database.
http://www-dep.iarc.fr/).
The common forms of both NHL and HL are derived
from clonal B cells at various stages of differentiation
and from specific B cell compartments. Whereas B cell
derived NHL cases retain many of the B cell lineage spe-
cific gene expression programs, the common (classical)
forms of HL exhibit loss of expression of B cell lineage
genes due to a variety of mechanisms [2-7]. Peripheral
T cell lymphomas (PTCL) are derived from post-thymic
T cells [8].
B cell-derived Hodgkin and Reed-Sternberg (H/RS)
cells of HL and the T cell-derived neoplastic cells of
Anaplastic Large Cell Lymphoma (ALCL) constitutively
express CD30, a 120 kDa surface phosphorylated glyco-
protein [9-11], currently named tumour necrosis factor
receptor superfamily, member 8 (TNFRSF8; HUGO
Gene Nomenclature Committee). CD30 does not have
disease-specificity, as it is an activation-associated anti-
gen expressed by activated T and B cells, HTLV-I or
HTLV-II transformed T cells, and EBV-transformed B
cells [12,13]. Since anti-CD30 antibodies are not
tumour-specific and may target reactive T and B cell
subsets [14,15], the creation of antibodies against HL-
specific cell surface targets that are not activation-asso-
ciated markers remains a desirable goal.
Although most patients with HL are cured with first-
line therapy, 15%-20% of patients with stage I-II HL and
35%-40% of patients with stage III-IV HL and adverse
risk factors relapse after first-line therapy [16,17].
Patients with relapsed or refractory HL are often given
second line, salvage chemotherapy followed by high-
dose chemotherapy and autologous stem cell transplant
(HDCT/ASCT). Patients who fail HDCT/ASCT have a
poor outcome [18-21].
Immunotherapy has also been tried in HL patients. As
most classical forms of HL express CD30 on the plasma
membrane of Reed-Sternberg (RS) cells, the neoplastic
cells in HL, various preparations of anti-CD30 antibo-
dies have been tried. These, when used as single-agent
therapy in patients who have failed salvage therapy,
show only modest effects [22]. Anti-CD30 immunother-
apy of HL using radioimmunoconjugates has been asso-
ciated with severe hematotoxicity [23].
We have recently developed and characterized 2 novel
murine monoclonal antibodies, anti-R23.1 and anti-
R24.1, that recognize a 21 kDa cell surface molecule
expressed by H/RS and ALCL cells, but not by phytohe-
magglutinin (PHA) activated CD30+ T lymphocytes
[24]. The anti-R24.1 antibody also recognises a forma-
lin-resistant epitope expressed in clinical cases of classi-
cal HL and aggressive NHL [24]. We have now
identified the 21 kDa protein as CYB5B which is
expressed on the plasma membrane of lymphoma cells
but not normal lymphocytes, reactive lymphocytes or
bone marrow precursor cells.
Results
Immunoprecipitation and Western Blots After Subcellular
Fractionation
Murine monoclonal antibodies anti-R23.1 and anti-
R24.1 both precipitated a protein of 21 kDa detected on
Western-blots (Figure 1A) as previously described [24].
When L428 HL cells were surface labelled with biotin
and then fractionated by binding of biotin-labelled cell
surface membrane proteins from cell lysates to NeutrA-
vidin Agarose, the surface membrane fractions after
Western blotting revealed the identical 21 kDa protein.
The control cell line, Jurkat, which by flow cytometric
analysis was shown to be surface negative (see below),
did not demonstrate the presence of the 21 kDa protein
in the biotin-labelled cell surface membrane fraction.
Both L428 and Jurkat, however, contained the 21 kDa
protein in the cytosolic (biotin negative) fraction (Figure
1B).
2D-Gel Analysis
Two dimensional (2-D) gel electrophoresis followed by
blotting onto a PVDF membrane, and probing with anti-
bodies R23.1 and R24.1, and goat-anti-mouse IgG
(Horseradish Peroxidase conjugated) revealed only one
specific spot on the membrane (Figure 2). Mass-Spec-
trometric (LC/MS/MS) analysis of the corresponding
spot cut out from a duplicate gel detected five peptides
which cover 25% of the CYB5B sequence (Figure 3).
RT-PCR and Sequence Analysis
RT-PCR amplified a fragment of 660 bp from mRNA
sample isolated from KMH2 (HL), L-428 (HL) and OCI/
LY19 (diffuse large B cell lymphoma) (Figure 4).
Sequence analysis revealed that there is no mutation/
deletion/insertion in the coding region of CYB5B (Figure
5).
Protein Array Analysis of R23.1 Antibody Binding Targets
A PEX protein array (Imagenes, GmbH) containing
approximately 16,000 bacterial clones expressing 10,000
human recombinant His-tagged proteins derived from
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Page 2 of 19cDNA libraries from various human tissues, including
testis, lymphocytes, fetal brain, lung and colon was
screened with the antibody R23.1. The antibody recog-
nised a single clone, RZPDp9028C1242 (Figure 6A),
which was derived from a PHA-induced T-lymphocyte
cDNA library. Sequencing of this clone revealed it
expresses full length CYB5B. The recombinant proteins
encoded by clone RZPDp9028C1242 (full length
CYB5B) and the clone RZPDp9028A0834 (expressing
the COOH terminal region of CYB5B) (Figure 6B) were
expressed and immunoblotted with both R23.1 and an
anti-His antibody (Figure 6C). R23.1 clearly recognises
the approx 21 kDa full-length CYB5B, but not the
COOH-region of the protein, revealing the epitope of
the antibody to lie within the first 70aa.
Gene Expression of CYB5B in HL, DLBCL and ALCL Cell
Lines
Gene expression was first assessed by quantitative PCR.
Quantitative PCR showed that HL cell lines KMH2 and
L428, as well as ALCL cell line DEL had high relative
expression levels using a universal human RNA refer-
ence (UHRR) as the calibrator, whereas DLBCL lines
DB and OCI-Ly19 had a more modest increase in
expression. ALCL cell line SR-786 showed no increase
in CYB5B mRNA in comparison to UHRR (Figure 7).
Gene expression of CYB5B was also measured in 5 HL
cell lines, HDLM2, KMH2, L1236, L428, and L540,
using Affymetrix GeneChip® Human Genome U133 Plus
2.0 Arrays. We used microdissected benign germinal
centre B cells as the calibrator. Two HL cell lines
(KMH2 and L428) had higher expression levels than
benign germinal centre B cells, whereas the others
Figure 1 Immunoprecipitation of the 21 kDa protein.P a n e lA :
Western-blot analysis of immunoprecipitated 21 kDa protein
(probed with anti-R23.1 MAb). Lane 1: MW = Bio-Rad Kaleidoscope
molecular weight markers. Lane 2: Protein immunoprecipitated by
R23.1. Lane 3: protein immunoprecipitated by R24.1. Both anti-R23.1
and anti-R24.1 MAbs precipitated a protein of ~21 kDa. Panel B:
Immunoblots (probed with anti-R23.1 MAb) of subcellular fractions
of cell lysates after separation of biotin-labelled surface proteins on
NeutrAvidin agarose beads. Lanes 1-3: Unlabelled controls (no biotin
label added to surface proteins). Lanes 4-6: Surface biotin labelled
protein samples. Lane 1 and 4: Total cell lysate not further
fractionated on NeutrAvidin agarose beads. Lanes 2 and 5: Proteins
(cytosolic) not bound to the NeutrAvidin agarose beads. Lane 6: Cell
surface biotin-labelled proteins eluted from the avidin-beads. The
results show that Jurkat and L428 cells contain the protein
recognised by anti-R23.1 MAb in the cytosolic fraction (Lane 5) and
but only L428 cells express the protein on the cell surface (Lane 6).
No protein was detected in eluted fractions from avidin beads in
the absence of surface biotin labelling (Lane 3), indicating no
evidence of non-specific binding of unlabelled proteins to avidin
beads.
Figure 2 2D-Gel and Western-blot analysis. Panel A: Coomassie Blue staining of 2D gel. Panel B: Western-blot analysis with R23.1. The doublet
in the circle is tropomyosin used as internal control. The arrow indicates the spot that reacted with R23.1 on the PVDF membrane.
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sion of CYB5B mRNA compared to germinal centre B
cells (Figure 8).
Submegabase Resolution Tiling Array CGH to Assess the
CYB5B Locus in HL and ALCL Cell Lines
Submegabase resolution tiling array CGH was used to
determine the status of the CYB5B locus at 16q22.1 in
HL and ALCL cell lines [25]. This showed gains at the
CYB5B locus at 16q22.1 in HL cell lines KMH2 and
L428 (Figure 9), but not in ALCL cell lines DEL and
SR786.
Expression of CYB5 Protein in HL Tissue Microarrays
A tissue microarray (TMA) of 199 cases of Hodgkin
Lymphoma was assembled in duplicate. Of these, 9
cases were of nodular lymphocyte predominance
(NLPHL) type, and the rest (190) of classical types.
Reed-Sternberg cells and their variants were present in
the TMA sections for evaluation in 180 cases. As sum-
marised in Table 1, 37% of cases of classical HL showed
moderate (2+) to intense (3+) membrane positivity.
When cases with both cytoplasmic staining and any
intensity for membrane staining were included, 87% of
all Classical types of HL were positive for CYB5B
expression. Examples of 2+ and 3+ membrane staining
patterns are shown in Figures 10 and 11, respectively. In
both examples, cytoplasmic staining is limited to the
Golgi zone and a cytoplasmic speckled pattern that
might reflect mitochondrial staining (this will require
verification by confocal microscopy). None of the cases
of NLPHL showed membrane positivity but 44% (4 of 9
cases) showed weak diffuse cytoplasmic staining.
Expression of CYB5B Protein in Reactive Lymph Nodes
Immunohistochemistry for CYB5B protein was con-
ducted on 6 reactive lymph nodes. These showed no
evidence of membrane positivity. However, variable dif-
fuse cytoplasmic staining was noted in centrocytes (Fig-
ure 12) and in isolated cells in the T zone. In one case
of dermatopathic lymphadenopathy, a condition which
is usually due to a reactive T cell response to various
types of dermatoses [26], intense cytoplasmic staining
was noted in the activated T cell zone in isolated cells
(Figure 13). No speckled pattern of staining in the cyto-
plasm was noted unlike in HL cases.
Flow Cytometric Analysis of Surface and Cytoplasmic
CYB5B Protein Expression in Jurkat Cells
Jurkat cells were previously reported to have no surface
expression of CYB5B protein by flow cytometry [24].
This was also confirmed by subcellular fractionation of
Jurkat cell lysates (Figure 1A). We also used permeabi-
lized Jurkat cells to demonstrate the presence of intra-
cellular CYB5B protein in the absence of plasma
membrane CYB5B (Figure 14) by flow cytometry. Cyto-
plasmic labelling of CYB5B by mAb R23.1-FITC was
blocked by unlabelled mAb R23.1 but not mouse isotype
control IgG1 (Figure 15) indicating that this was not a
result of non-specific binding of anti-R23.1 to permeabi-
lized cells.
Bone Marrow CD34+ Precursor Cells Do Not Express
CYB5B at the Plasma Membrane
Dual colour flow cytometry was used to assess the
plasma membrane expression of CYB5B on viable CD34
+ cells in normal bone marrow samples (Figure 16).
This showed that there is negligible expression of
CYB5B by CD34+ cells, with most samples showing 0%
positivity (mean% ± s.d. = 0.3 ± 0.4; Figure 17).
RT-PCR of CYB5B in T and B Cell Enriched Fractions from
Reactive Lymph Nodes, Tonsils, Normal Peripheral Blood
Lymphocytes and Bone Marrow Samples
CYB5B expression was detected by RT-PCR in the CD3
+e n r i c h e df r a c t i o n sa n di nt h eC D 1 9 +e n r i c h e d
Figure 3 Mass-Spectrometry data of protein isolated by 2D-gel electrophoresis. The protein was cleaved by Trypsin from C-term side of KR
unless next residue is P. Matched peptides are shown in Bold Red and sequence coverage is 25%.
Figure 4 RT-PCR amplification of CYB5B.T h eCYB5B gene was
amplified using mRNAs from L428, KMH2 and OCI/LY19 cells as
templates and CYB5B-F1 and R1 primer pairs. A DNA fragment of
660 bp was detected.
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blood mononuclear cells, and normal bone marrow
samples, but at lower levels than housekeeping gene
GAPDH (Figures 18 and 19), indicating no differential
increase of CYB5B mRNA in benign lymphocytes even
in reactive conditions.
Discussion
We recently described a novel 21 kDa cell surface and
cytoplasmic protein expressed by HL and ALCL cell
lines, other CD30+ non-Hodgkin lymphoma cell lines,
HRS cells in HL clinical biopsies, and the neoplastic
cells in biopsies from ALCL and aggressive NHL
patients[24]. Using two independent methods, we now
show that the protein is identical to a poorly charac-
terised molecule which has been postulated to be outer
mitochondrial membrane protein Cytochrome B5B
(CYB5B) based on incomplete (45.8%) homology to
Cytochrome B5A, an endoplasmic reticulum protein
[27]. The first method was a classic approach, first
separating all proteins from HL cell line L428 lysates by
2-dimensional gel electrophoresis, detecting the 21 kDa
protein of interest by immunoblotting with anti-R23.1
mAb and then cutting out the identical spot from a
duplicate gel and subjecting the extracted protein to
LC/MS/MS for peptide identification after trypsin diges-
tion. The resulting peptide sequence matched that of
the predicted CYB5B protein sequence. The second
method involved screening for anti-R23.1 mAb binding
to a protein array containing approximately 16,000 bac-
terial clones expressing 10,000 human recombinant His-
tagged proteins derived from cDNA libraries from
various human tissues, including testis, lymphocytes,
fetal brain, lung and colon. The antibody recognised a
single clone, RZPDp9028C1242, which was derived from
a PHA-induced T-lymphocyte cDNA library. There was
no cross reactivity with any other clone on the array,
indicating high specificity for the protein expressed by
clone RZPDp9028C1242. Sequencing of this clone
revealed that it expresses full-length CYB5B.
Since we had previously reported that PHA-activated
T cells do not express the 21 kDa protein at the cell
surface [24], the detection of CYB5B in a PHA-induced
T-lymphocyte cDNA library derived protein array may
seem like a contradiction. However, it should be pointed
out that PHA activated T cells contain intracellular
CYB5B, but do not express it on the cell surface, since
propidium iodide non-excluding (i.e. non viable and
therefore naturally permeabilized due to loss of mem-
brane integrity) PHA activated T cells bind anti-R23.1
mAb (unpublished observations). This is also seen in T
cell derived Jurkat cells which contain intracytoplasmic
CYB5B but lack plasma membrane expression of this
protein, as we have shown in this paper.
We next looked at the relative expression of CYB5B
mRNA in cell lines. Quantitative PCR, using universal
human reference RNA (UHRR; Stratagene) as the calibra-
tor, showed CYB5B gene expression was increased in HL
and NHL cell lines with the highest expression in ALCL
line DEL, followed by HL lines L428 and KMH2. Surpris-
ingly, ALCL cell line SR-786 showed no increase in
CYB5B expression. This was puzzling at first as we have
previously reported that SR-786 cells are positive for the
membrane protein labelled by mAb anti-R23.1 [24].
Figure 5 Sequence analysis of CYB5B cDNA. Panel A: The coding region of CYB5B contains no mutation/deletion/insertion. Panel B: 150 AA
translated from the CYB5B coding region.
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Page 5 of 19Figure 6 Protein array identification of the molecular target of R23.1. Panel A: A PEX protein array containing approximately 16,000
bacterial clones expressing human recombinant His-tagged proteins was screened with the antibody R23.1. The antibody recognised a single
clone, 9028C1242. Panel B and C: The clone 9028C1242 (full length CYB5B) and the clone 9028A0834 (expressing the COOH terminal region of
CYB5B) were expressed and Western immunoblotted with both R23.1 and an anti-His antibody. R23.1 clearly recognises the approximately 20
kDa full length CYB5B, but not the COOH-region of the protein, revealing the epitope of the antibody to lie within the first 70aa.
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Page 6 of 19Figure 7 Quantitative PCR of CYB5B expression in lymphoma cells lines. DLBCL (DB; OCI-LY19), HL (KMH2; L428), and ALCL (DEL; SR-786)
cell lines were compared against universal human reference RNA as the calibrator. Relative expression plotted.
Figure 8 Relative mRNA expression of CYB5B in 5 Hodgkin lymphoma cell lines compared to germinal centre B cells. Fold difference is
shown using normal germinal centre B cells (GC mean) as the control. Two HL cell lines L428 and KMH2 showed over 4-fold increase in CYB5B
mRNA expression, while 3 HL cell lines HDLM2, L1236 and L540 decreased or similar levels of CYB5B mRNA expression (Affymetrix probe set ID
238554_at).
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Page 7 of 19UHRR was developed at Stanford University by the Bot-
stein/Brown laboratory and is commercially available
from Stratagene. The original set of cell lines used to cre-
ate the pooled reference human RNA has not been fully
documented in indexed publications [28] but includes 3
different malignant lymphoid or histiocytic cell lines (his-
tiocytic lymphoma, presumed of macrophage origin, lym-
phoblastic lymphoma and a plasmacytoma which is of B
cell origin) [29]. It is possible therefore that UHRR con-
tains a relatively high concentration of CYB5B mRNA
and, if used as the calibrator, may lead to an underesti-
mation of CYB5B in cell lines such as SR-786 if it has
similar levels of the CYB5B mRNA.
We therefore used an additional platform to assess
CYB5B gene expression levels in HL cell lines using the
Affymetrix GeneChip® Human Genome U133 Plus 2.0
Arrays and used RNA from pooled benign germinal
centre B cells isolated from reactive lymph nodes by
microdissection as the calibrator. Since the HL cell lines
are derived from B cells, we felt benign reactive germ-
inal centre B cell-derived RNA would be suitable as a
calibrator. We noted, using this assay, that CYB5B
expression is increased in HL cell lines KMH2 and
L428, but not HDLM2, L1236, and L540. Again, there
remains a possibility that reactive germinal centre B
cells have increased expression of CYB5B,a n dt h i s
might lead to underestimation of relative mRNA levels
in the cell lines tested. We then looked at CYB5B
mRNA in fresh samples of normal T and B cells har-
vested from peripheral blood, reactive lymph nodes,
Figure 9 SMRT-Array CGH of HL and ALCL cell lines. High resolution karyogram of chromosome 16 showing amplification at 16q22.1 (arrow)
in HL cell lines KMH2 and L428 but not ALCL cell lines DEL and SR786.
Table 1 CYB5B Expression in Hodgkin Lymphoma Tissue Microarray Sections
Membrane Positivity 2+ to 3+ Cytoplasmic and all membrane positivity
Evaluable cases 180 180
NLPHL 9 9
Classical HL 171 171
Positive Cases Of Classical HL 64 (37%) 148 (87%)
Positive Cases Of NLPHL 0 (0%) 4 (44%)*
*Cytoplasmic only.
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GAPDH, an ubiquitous housekeeping gene, as the cali-
brator. There was no evidence of overexpression of
CYB5B mRNA in any of these samples. Thus the data
from the Affymetrix experiments may be a true reflec-
tion of increased CYB5B m R N Ai n2o f5H Lc e l ll i n e s
with no bias created by the calibrator.
Since there was evidence that HL cell lines KMH2 and
L428 consistently showed increased expression of
CYB5B mRNA regardless of the assay method used, and
ALCL cell line DEL also showed an increase at even
higher levels than the 2 HL cell lines, one of the possi-
ble explanations was amplification of the CYB5B gene in
these cell lines. Array CGH using a submegabase resolu-
tion tiling array revealed gains in the CYB5B locus in
HL cell lines KMH2 and L428, but not in ALCL cell
line DEL. Thus, although gene amplification may be a
mechanism of increased CYB5B mRNA levels in KMH2
and L428 cells, this is unlikely in DEL cells. The status
of amplification of the gene in clinical samples will be
necessary to determine if this is a clinically relevant
observation.
Figure 10 Immunohistochemical detection of CYB5B protein in
HL clinical biopsies. An example of 2+ membrane positivity for
CYB5B protein in Reed-Sternberg cells and mononuclear variants.
Note prominent Golgi staining (Red arrowhead) and cell membrane
detail showing a ruffled pattern (black arrow). Magnification × 600.
Figure 11 Immunohistochemical detection of CYB5B protein in
HL clinical biopsies. An example of intense (3+) positivity for
CYB5B on the cell membrane (black arrow) and Golgi (red
arrowhead) regions of Reed-Sternberg cells and mononuclear
variants. Note speckled cytoplasmic staining pattern (green
arrowhead). Magnification × 600.
Figure 12 Immunohistochemical detection of CYB5B protein in
reactive lymph node. Germinal centre centrocytes with
cytoplasmic expression of CYB5B protein. Membrane staining is not
evident. Magnification × 400.
Figure 13 Immunohistochemical detection of CYB5B protein in
reactive lymph node showing dermatopathic change. Intense
cytoplasmic staining for CYB5B in T-zone lymphocytes. Membrane
staining is not evident. Magnification × 600.
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CYB5B. Prior publications regarding the two mem-
brane-anchored isoforms of mammalian microsomal
and outer mitochondrial membrane Cytochrome b5
used the older nomenclature of MC b5 and OM b5 [20]
or cyt-b5 types 1 and 2 [27], respectively. The Cyto-
chrome B5 isoforms in mammals are electron transfer
molecules which have a heme binding extramembrane
domain (~100 residues) and a membrane anchoring
domain contained within the 10 polar C-terminal resi-
dues [21-23]. Much of the prior data on CYB5B relates
to the rat outer membrane protein rOM b5 which was
isolated from rat liver as a 92 residue fragment repre-
senting the heme-binding domain [30] and the cloned
gene showed it has 146 residues [31]. Aliases include
OMB5; CYB5-M; CYPB5 M; CYPB5 M; CYTB5, TYPE
2 and DKFZp686 M0619 [OMIM: *611964; GenBank:
AK291576; NM_030579; Gene ID 80777]. The CYB5B
gene is located on chromosome 16 (16q22.1; [OMIM:
*611964]). By similarity alone, but without experimental
evidence, human CYB5B has been so named due to par-
tial (45.8%) homology to CYB5A [27], and high homol-
ogy to rat outer membrane of mitochondrial protein
rOM b5 (74% sequence identity) [Ensembl:
ENSRNOG00000011142].
B5-domain proteins can be divided into two main
classes - those with a heme-binding cytochrome b5 fold
including Cytochrome b5, bacterial cytochrome b558,
flavocytochrome b2, sulfite oxidase, nitric reductase and
other oxidoreductases, and non-heme-bindings proteins
such as chitin synthases, probable E3 ubiquitin-protein
ligase HERC2 and the membrane-associated progester-
one receptor family MAPR [32]. MAPR family proteins
include neuron derived neurotrophic factor NENF or
neudesin [33], progesterone receptor membrane compo-
nent 1 (PGRMC1) [32] and progesterone receptor mem-
brane component 2 (PGRMC2) [34]. Possible paralogs
include the aquaporin family of water transport proteins
(Ishibashi,K.; Cytochrome b5 and aquaporins share the
last transmembrane amino acids sequence; unpublished;
http://www.uniprot.org/uniprot/O43169), and HERC2
ubiquitin transferase proteins and a number of chitin
synthases as mentioned above [35]. The KEGG site also
lists 10 paralogs including cytochrome b5 type A
(microsomal), fatty acid desaturase 2, fatty acid desatur-
ase 1, sulfite oxidase, cytochrome b5 reductase 4, fatty
Figure 14 Flow cytometric detection of CYB5B in Jurkat cells. Histograms show the fluorescence intensity distribution of R23.1-FITC-stained
Jurkat cells, stained either for cell-surface R23.1 on viable cells (black solid line) or intracellular R23.1 within fixed cells (gray dashed line). There is
no detectable surface labelling whereas intracellular labelling is evident.
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Page 10 of 19Figure 15 Flow cytometric detection of CYB5B in Jurkat cells. Histograms show the fluorescence intensity distribution of R23.1-FITC-stained,
fixed/permeabilized Jurkat cells blocked either with control mouse IgG (black solid line) or unlabelled R23.1 (gray dashed line). Whereas blocking
with unlabelled R23.1 mAb inhibited intracellular binding of R23.1-FITC, a similar effect was not seen with control IgG.
Figure 16 Flow cytometric detection of CYB5B in bone marrow precursor cells. Bone marrow cells were gated for viable lymphocytes
using forward vs. side scatter and propidium iodide exclusion, and then analysed for surface CD34-APC and R23.1-FITC expression. Numbers
indicate the percentages of the total cells in the plot falling into the indicated gates. In this example, 0.4% of cells expressed dim CD34 and
R23.1 and none coexpressed CD34 hi (bright) and R23.1.
Murphy et al. Molecular Cancer 2010, 9:14
http://www.molecular-cancer.com/content/9/1/14
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and RLD 2, cytochrome b5 domain containing 1, and
aquaporin 4 http://ssdb.genome.jp/ssdb-bin/ssdb_para-
log?org_gene=hsa:80777.
As most of the related molecules are secreted proteins
(NENF) or endoplasmic reticulum proteins (PGRMC1
and 2), the presence of CYB5B at the plasma membrane
of HRS and ALCL cells is unexpected. However, endo-
plasmic reticulum tail-anchored proteins with short
hydrophobic domains such as the CYB5A isoform, if
lengthened by any inserted sequence of as few as 5
amino acids, can be induced to relocate to the plasma
membrane [36,37]. When we checked the CYB5B gene
in HL cells for mutations that might lengthen the
hydrophobic domain we found none, thus this explana-
tion does not appear to hold true in human lymphoma
cells. The presence of unmutated CYB5B in the plasma
membrane of HL and NHL cells suggests that the
Figure 17 Results of flow cytometric detection of CYB5B in
bone marrow precursor cells. Vertical scatter plot of the incidence
of R23.1+ cells in the CD34-hi gate. Data shown are the percentage
of all CD34-hi cells which are also R23.1+ from 9 different normal
bone marrow samples. Mean percentage ± s.d. = 0.3 ± 0.4.
Figure 18 Relative levels of CYB5B mRNA expression in T and B lymphocytes isolated from reactive lymph nodes and tonsils.R T - P C R
for GAPDH and CYB5B from RNA extracted from lymph node (LN) and tonsil lymphocytes enriched for CD3+ T cells and CD19+ B cells showed
no increase in CYB5B mRNA in comparison to GAPDH.
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brane by an alternate mechanism. Such mechanisms
could include other post-translational changes that
result in altered hydrophobicity [38,39], differences in
glycosylation [38] or interaction with one or more mole-
cular chaperones or heat shock proteins [40,41].
Although the function of human CYB5B protein is
poorly characterised at this time and the mechanism of
its trafficking to the plasma membrane of Hodgkin and
aggressive non-Hodgkin lymphoma cells is unexplained,
the protein could be a useful target for antibody-based
therapy as it is not expressed at the plasma membrane
of normal lymphocytes, reactive lymphocytes, or bone
marrow precursor cells. Toxicity, therefore, might be
minimal if anti-CYB5B antibodies are used for targeted
therapy of CYB5B surface positive lymphomas.
Conclusions
Anti-R23.1 and anti-R24.1 MAbs recognise a 21 kDa
plasma membrane and cytoplasmic protein expressed by
HL and aggressive NHL that is identical to CYB5B, a
protein that has been putatively named as an outer
membrane mitochondrial protein based on partial simi-
larities to CYB5A, an endoplasmic reticulum tail-
anchored protein and high sequence identity with rat
outer membrane mitochondrial protein rOM b5. The
encoding gene is unmutated in HL cell lines. The pre-
sence of unmutated CYB5B in the plasma membrane of
H La n dN H Lc e l l ss u g g e s t st h a tt h ep r o t e i ni sl i k e l yt o
be translocated to the plasma membrane by a hitherto
unknown mechanism.
CYB5B gene expression is increased in HL and NHL
cell lines with the highest expression in ALCL line DEL,
Figure 19 Quantification of CYB5B RT-PCR data from clinical samples. cDNA was prepared from both CD3-selected and CD19-selected cells
from normal peripheral blood mononuclear cells (PBMNC), reactive tonsils, normal bone marrow (BM) and reactive lymph node samples. PCR
was performed using primers to the GAPDH housekeeping gene. Bands from the GAPDH PCR were used to normalize loading for the CD3+ and
CD19+ cDNA pools for each specimen. Then, PCR was performed in duplicate for CYB5B and GAPDH, using the same amount of cDNA and the
same number of cycles. Bands were quantified using spot densitometry and the ratio of CYB5B/GAPDH signal was calculated. Values shown are
from a typical experiment; each sample was analyzed by at least two independent PCRs. In none of the samples did the CYB5B signal exceed
that of GAPDH.
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ciated with CYB5B amplification in HL cell lines KMH2
and L428, but not in ALCL cell line DEL. CYB5B
mRNA expression is not increased in reactive lympho-
cytes but the CYB5B protein is present in detectable
quantities in the cytoplasm of such cells. The protein is
not expressed at the plasma membrane of bone marrow
precursor cells, but using immunohistochemistry on tis-
sue microarrays of clinical cases of HL, plasma mem-
brane and/or cytoplasmic expression was detected in HL
neoplastic HRS cells in 87% of clinical cases, with
intense membrane staining in 37% of clinical cases. The
plasma membrane expression of CYB5B protein in neo-
plastic cells in HL is potentially useful for antibody-
based targeted therapy in a subset of patients especially
those with high levels of membrane expression. Since
normal lymphocytes and bone marrow precursor cells
lack surface expression of CYB5B, little or no toxicity
should be observed during anti-CYB5B immunotherapy.
Methods
All experimental protocols were reviewed and approved
by the University of British Columbia (UBC) Research
Ethics Board (REB) (Certificate #H06-60016).
Cell Lines, Cell Culture Conditions
The human HL-derived cell lines KM-H2, L-428 and the
ALCL cell lines DEL and SR-786 were obtained from
the Deutsche ammlung von Mikrooganism und Zellkul-
turen GmbH (Braunschweig, Germany). All cell lines
were cultured in RPMI 1640 supplemented with 10%
heat-inactivated fetal bovine serum (Cansera Inc., Etiobi-
coke, ON, Canada), L-glutamine and penicillin and
streptomycin in a humid environment of 5% CO2 at 37°
C to a density of 10
6 cells/ml.
Cell Lysate Preparation
HD lymphoma cell line, L-428, was cultured in IMDM
complete media (10% FBS, with penicillin/streptomycin/
fungizone, Gibco) for 48 hrs. The cultured cell was har-
vested and pelleted at ~1000 g for 5 minutes. The cells
were washed in PBS (pH7.2) for 3 times and lysed in
Mammalian protein extraction buffer supplied by Pierce.
The samples were incubated on ice for 10 minutes and
pelleted at 10,000 × g for 10 min. The supernatant was
transferred to fresh tubes.
Formation of the Antibodies and Protein G Beads
Complex
100 μl of protein G beads (50%) (Pierce) were added to
each micro-centrifuge tube. The beads were pelleted at
<2000 g for 30 seconds and washed in 1 ml of PBS once.
200 μlo fP B Sa n d5μg of antibodies were added to each
tube. The beads were incubated at room temperature for
at least 2 hrs and washed in PBS twice. Normal mouse
IgG was coupled to the protein A beads in the same way
and these beads are used for pre-clearing the lysates.
Antigen Capture
400 μl of the sample was incubated with normal mouse
IgG-protein-A beads for 1 hr at room temperature and
transferred into the tube containing mAb-protein A
complexes. The beads were then incubated at 4°C over-
night and washed in 1 ml of PBS for 3 times. The beads
were resuspended in 1 ml of PBS and 50 μlo fb e a d s
were transferred into another 1.5 ml tube. The beads
were pelleted and as much buffer as possible was
removed. The original tube was stored at -20°C.
SDS-Page and Western-Blot Analysis
25 μl of the 1 × SDS sample buffer was added to the
second tube and heated at 100°C for 5 min. The tube
was centrifuged 13000 ×g briefly and the sample was
loaded to 4-20% Tris-Glycine gel (Bio-Rad). The samples
were separated at 120 V for 80 min. The gels were equi-
librated in pre-chilled 1× transfer buffer and the pro-
teins were then transblotted onto a nitrocellulose
membrane at 90 volts for 60 min. Western-blot analysis
with R24.1/R23.1 was performed by blocking the mem-
brane in 5% non-fat-dry milk, and probing with primary
antibody (R24.1/R23.1) and secondary antibody (goat-
anti-mouse IgG-AP) sequentially. The protein band
which reacted with the antibody was visualized in BCIP/
NBT substrate. The original tube was submitted to Ken-
drick Laboratories, Inc. (Madison, WI, USA) for 2D-gel
analysis after the Western-blot analysis confirmed the
candidate protein was pulled down by the antibody.
Surface Protein Labelling
Surface protein labelling with biotin was performed with
the Pierce Cell Surface Protein Isolation Kit as per the
manufacturer’s instructions (Thermo Fisher Scientific,
Fisher Canada, Nepean, Ontario). Briefly, Jurkat and L-
428 cells were cultured in RPMI 1640 (STEMCELL
Technologies, Vancouver, British Columbia, Canada)
with 10% FBS, and 1× Antibiotic Antimycotic (GIBCO
Invitrogen Canada Inc. Burlington, Ontario) for 48 hrs.
Cells were harvested and washed twice in ice-cold PBS
and counted. 2.5 × 10
7 cells were used for surface label-
ling. One vial of Sulfo-NHS-SS-Biotin was dissolved in
48 ml of ice-cold PBS. 24 ml of the biotin solution were
added to each labelling tube. PBS was used to replace
the Sulfo-NHS-SS-Biotin for the control tubes. The
tubes were placed on a rocking platform for 30 minutes
at 4°C. 500 μl of Quenching Solution were added to
each tube to quench the reaction. 20 ml of TBS were
added to each tube and the cells were centrifuged at
500 × g for 3 minutes. The cells were washed twice in
20 ml of TBS and lyzed in 500 μl of lysis buffer with
protease inhibitor. The samples were transferred into
1.5 ml microcentrifuge tubes and incubated on ice for
30 min. The samples were vortexed every 5 min for 5
seconds and centrifuged at 10,000 g for 2 min at 4°C.
500 μl of the NeutrAvidin Agarose slurry were added to
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for 3 times. The supernatants were incubated in the col-
umns for 60 min at room temperature on with end-
over-end mixing using a rotator. The columns were cen-
trifuged at 1,100 × g for 1 min and the flow-throughs
were transferred to fresh tubes. The columns were
washed in 500 μl Wash buffer 4 times. 400 μlo fS D S -
Page sample buffer were added to each column and the
columns were incubated at room temperature for 1 hr
with the end-over-end mixing. The columns were cen-
trifuged at 1,000 × g for 3 minutes and the eluted sam-
ples were analyzed on 4-20% Tris-HCl gel (Bio-Rad
Laboratories (Canada) Ltd. Mississauga, Ontario). SDS-
PAGE and Western-blot analysis was performed follow-
ing the same protocol as described above.
2D-Gel Analysis and Coomassie-Blue Staining
Two-dimensional electrophoresis was performed accord-
ing to the carrier ampholine methods [42] as follows:
Isoelectric focusing was carried out in glass tubes of
inner diameter 2.0 mm using 2% pH 3.5-10 (GE Health-
care, Piscataway, NJ) for 9600 volt-hrs. One μgo fa n
IEF internal standard, tropomyosin, was added to each
sample. This protein migrates as a doublet with lower
polypeptide spot of MW 33,000 and PI 5.2; an arrow on
the stained gels marks its position. The enclosed tube
gel pH gradient plot for this set of ampholines was
determined with a surface pH electrode. After equilibra-
tion for 10 min in Buffer ‘O’ (10% glycerol, 50 mM
dithiothreitol, 2.3% SDS and 0.0625 M Tris, pH 6.8) the
tube gels were sealed to the top of stacking gels on top
of 10% acrylamide slab gels (0.75 mm thick) and SDS
slab gel electrophoresis carried out for about 4 hrs at
12.5 mA/gel. The following proteins (Sigma Chemical
C o . ,S t .L o u i s ,M O )w e r ea d d e da sm o l e c u l a rs t a n d a r d s
to a well in the agarose that sealed the tube gel to the
slab gel: myosine (220,000), phosphorylase A(94,000),
catalyse (60, 000), actin (43, 000), carbonic anhydrase
(29,000) and lysozyme (14, 000). These standards appear
as bands at the basic edge of the Coomassie blue-stained
10% acrylamide slab gel. The gel was dried between
sheets of cellophane with the acid end to the left.
After slab gel electrophoresis, the gel for blotting was
transferred to transfer buffer (12.5 mM Tris, pH8.8, 86
mM Glycine, 10% MeOH) and transblotted onto PVDF
paper overnight at 200 mA at approximately 100 volts/
two gels. Gel ID numbers are indicated in the lower
acid corner of the membrane.
Western-blot analysis was performed on PVDF paper.
The PVDF paper was incubated in 5% non-fat dry milk
for 2 hrs followed by an incubation in primary antibody
(1:1000 diluted R24.1/R23.1) at 4°C overnight. The
PVDF was washed in PBS 4 times and then incubated in
goat-anti-mouse IgG-HRP conjugate (1:2000) at room
temperature for 2 hrs. The paper was washed 4 times in
PBS and incubated in 10 ml of SuperSignal West Pico
Chemiluminescent substrate (Pierce Biotech., Rockford,
IL) fro 10 min. A Kodak BioMAx MS film was exposed
to the PVDF paper in a film cassette. The protein spot
on a duplicate dried 2D gel was cut and submitted to
Protein Chemistry Core Facility in Columbia University
(New York, New York) for LC/MS/MS analysis.
RT-PCR and Sequence Analysis
cDNAs of CYB5B were amplified from mRNA with
Clontech’s Titanium One Step RT-PCR kit (Clontech,
M o u n t a i nV i e w ,C A ,U S A ) .T h ef o r w a r dp r i m e ri s5 ’-
CTCAAGGAAAGTAGTCGCGG-3’, which starts at the
first nucleotide of 5’ end of the mRNA. The reverse pri-
mer is 5’-AACTCTTGGCCTCAAGCGA-3’, which starts
at the nucleotide 660. A product of 660 bp is expected
to be amplified using this primer pair. The amplified
RT-PCR products were gel purified with Spinprep Gel
DNA kit (Novagen, Gibbstown, NJ, USA). The purified
samples were submitted to MacrogenUSA Inc. (Rock-
ville, MD, USA) for sequencing.
Protein Arrays
The protein arrays used in this study are the PEX arrays
from Imagenes (Berlin). Each array contains 16,000
Escherichia coli His-tagged expression clones from a
variety of expression libraries arrayed in a 3 × 3 pattern
on PVDF membranes. The expression vector used is
pQE30NST (GenBank Accession No. AF074376) and it
is transformed into E. coli strain SCS1 (Stratagene)
[43,44]. Sequence information for individual clones
recognized by antibodies was provided by Imagenes.
Antibody Screening
Prior to antibody screening, the arrays are prepared by
removing the dried colonies from the PVDF membranes
with tissue paper and TBSTT (TBS supplemented with
0.05% Tween 20 and 0.5% TritonX-100). This is followed
by three washes, for 20 min each, in TBST (TBS supple-
mented with 0.05% Tween 20) and blocked with 3% (w/v)
milk powder in TBST for 3 h at room temperature, the fil-
ters were incubated overnight with the monoclonal anti-
body R23.1 [24] at a 1:1000 dilution in 2% BSA/TBST.
Primary antibody incubation was followed by three washes
of 20 min each in TBST, and the protein arrays were then
incubated with the secondary antibody, alkaline phospha-
tase-conjugated (AP) anti-mouse IgG (A1418; Sigma,) for
1.5 h. Following three washes for 20 min each in TBST,
the filters were incubated for 10 min in AP buffer (1 mM
MgCl2, 100 mM Tris-Cl, pH 9.5) and 5 min in 0.125 mM
Attophos in AP buffer. Filters were illuminated with long-
wave UV light (460 nm EPI) and images were taken using
a high resolution CCD camera (Fuji LAS 3000; Fuji Film
Global)). Image analysis was performed using VisualGrid
(VisualGrid™ is available as a free download from (GPC
Biotech, Munich, Germany) and the identities of detected
clones were confirmed by sequencing.
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The E. coli expression clones 9028C1242 and
9028A0834 from the PEX library were grown in 5 ml
liquid cultures and protein expression induced with 1
mM IPTG and purified as previously described using
nickel affinity chromatography [43,45]. The size of each
purified protein was determined using SDS PAGE and
Coomassie staining.
Western Blotting
The purified proteins were separated by SDS PAGE and
transferred onto PVDF membranes at 100 V for 1 1/2
hr. The membrane was blocked for 2 hr in 3% Marvel/
TBST, washed in TBS (3 × 10 min) and incubated for 2
hr with the primary antibody as described above. Anti-
body binding was detected using an alkaline phospha-
tase-conjugated anti-mouse, or anti-rabbit, IgG
secondary antibody (Sigma) and visualized on a Fuji
LAS 3000 imager.
SMRT-Array CGH and Gene Expression Profiling
Tiling path array comparative genomic hybridization
was performed as described previously [25]. Genomic
DNA was extracted via standard proteinase K/RNAse
treatment and phenol-chloroform extraction.
Briefly, 200 ng of test and reference DNA were sepa-
rately labelled with Cyanine3-dCTP and Cyanine5-dCTP
(Perkin Elmer Life Sciences Inc., Boston, MA, USA),
respectively, via random priming at 37°C for 16-18 h in
t h ed a r k .L a b e l l e ds a m p l ea n dr e f e r e n c eD N Ap r o b e s
were combined, precipitated, re-suspended, blocked and
hybridized onto BAC arrays containing 26,819 clones
spotted in duplicate on a single slide. After hybridiza-
tion, arrays were washed, rinsed, and dried using an oil
free air stream. Slides were scanned using a charge-
coupled device (CCD) based imaging system (array-
WoRx eAuto, Applied Precision, Issaquah, WA, USA).
Images were analyzed using SoftWoRx Tracker Spot
Analysis software (Applied Precision). The ratios were
normalized using a stepwise normalization technique to
remove any biases added from non-biological sources.
Custom software (SeeGH) [46] was used to visualize
normalized data as log2 ratio plots. Genomic alterations
were classified as homozygous deletions, loss, normal,
gain, and amplification for ratios < -1.0, -1.0 to -0.15,
-0.15 to 0.15, 0.15 to 1.0, and >1.0 respectively [47].
SeeGH is now freely available from http://www.flintbox.
ca/technology.asp?page=312.
Relative Expression of CYB5B in Cell Lines Using qRT-PCR
and Affymetrix GeneChip® Human Genome U133 Plus 2.0
Arrays
Validation of the expression of CYB5B was carried out
by quantitative real-time PCR (qRT-PCR) using SYBR
green chemistry. Total RNA from DB, OCI-LY19,
KMH2, L428, DEL and SR-786 cell lines was extracted
using TRIzol reagents (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s protocol. cDNA synth-
esis was conducted using SuperScript III First-Strand
Synthesis SuperMix for qRT-PCR (Invitrogen, Carlsbad,
CA, USA) from the RNA samples and UHRR (Universal
Human Reference RNA). GAPDH was used as endogen-
ous control. After first strand synthesis, an equivalent of
16 ng of cDNA were added to three triplicate PCR reac-
tions containing SYBR GreenER qPCR SuperMix for
ABI PRISM® (Invitrogen, Carlsbad, CA, USA), 10 μM
forward primer and 10 μM reverse primer in a final
volume of 10 μl. The SYBR GreenER qPCR SuperMix
contains ROX (6-carboxy-X-rhodamine), the passive
reference fluorochrome that normalizes for pipetting
volume errors. Each reaction was performed in triplicate
in 384-well Optical reaction plates that cycled for 2 min
at 50°C, 95°C for 10 minutes, followed by 40 cycles of
95°C for 15 seconds, and 60°C for 1 minute on 7900 HT
Fast Real-Time PCR System (Applied Biosystems, CA,
USA). Fluorescent data were converted into cycle
threshold (CT) measurements using the 7900 HT-sys-
tem sequence detection systems (SDS) software and
were exported to Microsoft Excel. The Comparative CT
Method calculates relative gene expression using the
equation:
Relative Quantity
Delta Delta Ct 
 2
Affymetrix GeneChip® Human Genome U133 Plus 2.0
Arrays containing the CYB5B probe set 238554_at were
used to assess the expression of CYB5B in HL cell lines
in comparison to microdissected normal germinal centre
B cells. Microdissection was preformed on a Zeiss Axio-
plan 2 microscope equipped with mmi CellCut Plus
(Molecular Machines Industries’;H a s l e t t ,M I ,U S A )
Technology using 6 μm sections from reactive tonsil tis-
sue. Total RNA was extracted using Allprep extraction
kits (Qiagen, ON, Canada) and cRNA preparation was
performed following the routine protocol for 2-cycle
labeling reactions. 11 μg of labeled cRNA were then
hybridized on the array overnight and the arrays were
washed, stained and scanned using Affymetrix Fluidics
Station 450 and Affymetrix GeneChip Scanner (Affyme-
trix Inc.; Santa Clara, CA). All microarrays passed
homogeneous criteria for testing quality control includ-
ing present call rates >30% and normalized unscaled
standard errors <1.05 (NUSE). Affymetrix gene expres-
sion data was pre-processed and normalized by Robust
Multichip Average (RMA) in R using Bioconductor [48].
Flow Cytometric Analysis of Surface Expression of CYB5B
on Bone Marrow CD34+ Cells
Bone marrow aspirates were depleted of red blood cells
by either treating them with Red Blood Cell Lysis Buffer,
or using by Ficoll-Paque Plus density gradient centrifu-
gation (GE Healthcare); each method gave similar
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IgG (Invitrogen) for 20 minutes at 4°C, then washed
with 4 volumes PBS+2%FBS. Cells were stained using
APC-conjugated anti-CD34 (1/50, StemCell Technolo-
gies) and FITC-conjugated R23.1 antibody (1/50), for 45
minutes at 4°C. Cells were again washed with PBS+2%
FBS, then resuspended in PBS+1 ug/mL propidium
iodide, incubated on ice 10 minutes, then fixed with an
equal volume of 2% formaldehyde. Cells were then ana-
lyzed on a BD FacsCalibur and using FCS Express
software.
RT-PCR Analysis of CYB5B Expression in Normal
Peripheral Blood and Bone Marrow Samples Enriched for
T and B Cell Subpopulations
Cells were separated using Easy-Sep CD3+ or CD19+
magnetic bead-conjugated antibodies (Stem Cell Inc.).
RNA was extracted using Trizol reagent (Invitrogen)
and up to 2.5 ug of total RNA was reverse-transcribed
(Superscript II, Invitrogen). GAPDH primers were used
to normalize cDNA loading; when appropriate, cDNAs
were diluted using the same buffer composition as used
to perform reverse transcription. GAPDH and CYB5B
PCRs were carried out in duplicate tubes under the
same cycling conditions and run out on the same gel at
the same time (1× TAE, 2% agarose). Bands were quan-
tified using Fluorchem 3.04A (Alpha Innotech
Corporation).
PCR conditions: 95°C 1 min, 94°C 15 s-56°C 15 s-72°C
15 s for 32 cycles, 72°C for 5 minutes, hold at 4°C.
Primers (designed using Primer3, http://frodo.wi.mit.
edu/) were as follows:
hGAPDH-F: CAGCAAGAGCACAAGAGGAAGAGA
hGAPDH-R: TTGATGGTACATGACAAGGTGCGG
(160 bp)
hCYB5B-F: CTTCTGATGCCAGAGAAATGC
hCYB5B-R: GGATTTGCTTTCCGATGTGTA (197
bp)
Flow Cytometric Analysis of Surface and Cytoplasmic
CYB5B Protein Expression in Cell Lines
Jurkat T-cells (5 × 10
6 per tube) were blocked with 1/50
control mouse IgG, then labelled on the cell surface
with 1/50 of R23.1-FITC, then washed twice with PBS
+2%FBS, stained for non-viable cells using propidium
iodide, and fixed in 1% formaldehyde. Alternatively, iso-
type control IgG-blocked cells were resuspended in
Cytofix/Cytoperm solution (BD Biosciences Cytofix/
Cytoperm Fixation/Permeabilization Solution Kit), then
incubated with 1/100 of R23.1-FITC conjugated mAb.
Cells were analyzed using a BD FACSCalibur and FCS
Express (version 3, DeNovo Software, Los Angeles).
For blocking experiments, Jurkat T-cells (5 × 10
6 per
tube) were blocked with 1/50 isotype control mouse
IgG1, then washed and resuspended in Cytofix/Cyto-
perm solution as per manufacturer’s directions.
Permeabilized cells were then resuspended in 25 uL and
incubated with isotype control IgG1 or unlabelled R23.1
antibody (1/25 of either) for 30 minutes at 4°C. Then,
25 uL containing 0.5 uL R23.1-FITC was added, and
cells were incubated an additional 30 minutes at 4°C.
Cells were analyzed using a BD FACSCalibur and FCS
Express (version 3, DeNovo Software, Los Angeles).
Acknowledgements
This study was funded through operating grants to DB and AK from the
Canadian Institutes of Health Research, with additional support to DB from
the Trudi Desmond Memorial Fund, the British Columbia Cancer Agency, the
Department of Pathology and Laboratory Medicine, University of British
Columbia Endowment Fund, and a Fellowship grant to MZ from the
Lymphoma Foundation Canada. Laboratory equipment grants were
generously provided to DB by the British Columbia Cancer Foundation.
Two dimensional gel electrophoresis was performed at the Kendrick
Laboratories, Inc. (Madison, WI, USA) and LC/MS/MS identification of CYB5B
was performed at the Protein Chemistry Core Facility in Columbia University
(New York, New York). CYB5B amplicon sequencing was performed at
MacrogenUSA Inc. (Rockville, MD, USA).
We thank Sandy Sung and Fred Wong for their expertise in separating T and
B cell enriched fractions from clinical samples.
Author details
1Centre for Human Proteomics, Royal College of Surgeons in Ireland, 126 St
Stephen’s Green, Dublin 2, Ireland.
2Centre for Translational and Applied
Genomics, British Columbia Cancer Agency, Provincial Health Services
Authority Laboratories, 600 West 10th Avenue, Vancouver, British Columbia,
V5Z 4E6, Canada.
3British Columbia Cancer Research Centre, 675 West 10th
Avenue, Vancouver, British Columbia, V5Z 1L3, Canada.
4University of
Botswana, Biomedical Sciences, School of Medicine, Private Bag UB 0022,
Gaborone, Botswana.
Authors’ contributions
DM and HC performed the protein array identification of CYB5B, full length
expression and Western blotting of recombinant CYB5B. MZ performed
immunoprecipitation of CYB5B, subcellular fractionation, Western blotting of
2-D gel transfers to PDVF paper, RT-PCR experiments, and gel purification of
CYB5B amplicons. JP performed RT-PCR on clinical samples and flow
cytometric analysis of bone marrow samples. FF and CS performed the array
CGH and gene expression studies. RDG provided HL TMA sections and TMA
sector maps. DB and AK were responsible for planning, directing of the
research as principal investigators, obtaining research funding, performing
literature searches and coordinating the experiments between the DB, AK
and DM laboratories and editing the final version of manuscript. All authors
contributed equally to the drafting of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 9 November 2008
Accepted: 26 January 2010 Published: 26 January 2010
References
1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J,
Vardiman JW: WHO Classification of Tumours IARC 2008, 2.
2. Jundt F, Acikgoz O, Kwon SH, Schwarzer R, Anagnostopoulos I, Wiesner B,
Mathas S, Hummel M, Stein H, Reichardt HM, Dorken B: Aberrant
expression of Notch1 interferes with the B-lymphoid phenotype of
neoplastic B cells in classical Hodgkin lymphoma. Leukemia 2008,
22:1587-1594.
3. Tedoldi S, Mottok A, Ying J, Paterson JC, Cui Y, Facchetti F, van Krieken JH,
Ponzoni M, Ozkal S, Masir N: Selective loss of B-cell phenotype in
lymphocyte predominant Hodgkin lymphoma. J Pathol 2007, 213:429-440.
4. Kluiver J, Kok K, Pfeil I, de Jong D, Blokzijl T, Harms G, Vlies van der P,
Diepstra A, Atayar C, Poppema S, et al: Global correlation of genome and
Murphy et al. Molecular Cancer 2010, 9:14
http://www.molecular-cancer.com/content/9/1/14
Page 17 of 19transcriptome changes in classical Hodgkin lymphoma. Hematol Oncol
2007, 25:21-29.
5. Doerr JR, Malone CS, Fike FM, Gordon MS, Soghomonian SV, Thomas RK,
Tao Q, Murray PG, Diehl V, Teitell MA, Wall R: Patterned CpG methylation
of silenced B cell gene promoters in classical Hodgkin lymphoma-
derived and primary effusion lymphoma cell lines. J Mol Biol 2005,
350:631-640.
6. Ushmorov A, Ritz O, Hummel M, Leithauser F, Moller P, Stein H, Wirth T:
Epigenetic silencing of the immunoglobulin heavy-chain gene in
classical Hodgkin lymphoma-derived cell lines contributes to the loss of
immunoglobulin expression. Blood 2004, 104:3326-3334.
7. Schwering I, Brauninger A, Klein U, Jungnickel B, Tinguely M, Diehl V,
Hansmann ML, Dalla-Favera R, Rajewsky K, Kuppers R: Loss of the B-
lineage-specific gene expression program in Hodgkin and Reed-
Sternberg cells of Hodgkin lymphoma. Blood 2003, 101:1505-1512.
8. O’Leary H, Savage KJ: The spectrum of peripheral T-cell lymphomas. Curr
Opin Hematol 2009, 16:292-298.
9. Stein H, Foss HD, Durkop H, Marafioti T, Delsol G, Pulford K, Pileri S, Falini B:
CD30(+) anaplastic large cell lymphoma: a review of its histopathologic,
genetic, and clinical features. Blood 2000, 96:3681-3695.
10. Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H: Molecular
cloning and expression of a new member of the nerve growth factor
receptor family that is characteristic for Hodgkin’s disease. Cell 1992,
68:421-427.
11. Schwarting R, Gerdes J, Durkop H, Falini B, Pileri S, Stein H: BER-H2: a new
anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant
epitope. Blood 1989, 74:1678-1689.
12. Segal GH, Kjeldsberg CR, Smith GP, Perkins SL: CD30 antigen expression in
florid immunoblastic proliferations. A clinicopathologic study of 14
cases. Am J Clin Pathol 1994, 102:292-298.
13. Stein H, Mason DY, Gerdes J, O’Connor N, Wainscoat J, Pallesen G, Gatter K,
Falini B, Delsol G, Lemke H, et al: The expression of the Hodgkin’s disease
associated antigen Ki-1 in reactive and neoplastic lymphoid tissue:
evidence that Reed-Sternberg cells and histiocytic malignancies are
derived from activated lymphoid cells. Blood 1985, 66:848-858.
14. Vinante F, Krampera M, Morosato L, Rigo A, Romagnani S, Pizzolo G:
Peripheral T lymphocyte cytokine profile (IFNgamma, IL-2, IL-4) and
CD30 expression/release during measles infection. Haematologica 1999,
84:683-689.
15. Paloczi K, Pocsik E, Kotlan B, Ujhelyi E, Timar L, Petranyi GG: The pattern of
activation antigen expression on T-lymphocyte subpopulation in
infectious mononucleosis. Haematologia (Budap) 1991, 24:83-90.
16. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D,
Tesch H, Herrmann R, Dorken B, Muller-Hermelink HK, et al: Standard and
increased-dose BEACOPP chemotherapy compared with COPP-ABVD for
advanced Hodgkin’s disease. N Engl J Med 2003, 348:2386-2395.
17. Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM,
Canellos GP, Peterson BA: Randomized comparison of ABVD and MOPP/
ABV hybrid for the treatment of advanced Hodgkin’s disease: report of
an intergroup trial. J Clin Oncol 2003, 21:607-614.
18. Mendler JH, Friedberg JW: Salvage therapy in Hodgkin’s lymphoma.
Oncologist 2009, 14:425-432.
19. Seftel M, Rubinger M: The role of hematopoietic stem cell transplantation
in advanced Hodgkin Lymphoma. Transfus Apher Sci 2007, 37:49-56.
20. Fung HC, Stiff P, Schriber J, Toor A, Smith E, Rodriguez T, Krishnan A,
Molina A, Smith D, Ivers B, et al: Tandem autologous stem cell
transplantation for patients with primary refractory or poor risk
recurrent Hodgkin lymphoma. Biol Blood Marrow Transplant 2007,
13:594-600.
21. Kewalramani T, Nimer SD, Zelenetz AD, Malhotra S, Qin J, Yahalom J,
Moskowitz CH: Progressive disease following autologous transplantation
in patients with chemosensitive relapsed or primary refractory Hodgkin’s
disease or aggressive non-Hodgkin’s lymphoma. Bone Marrow Transplant
2003, 32:673-679.
22. Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R, Keler T,
Graziano R, Blanset D, Yellin M, et al: Phase I/II study of an anti-CD30
monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic
large-cell lymphoma. J Clin Oncol 2007, 25:2764-2769.
23. Schnell R, Dietlein M, Staak JO, Borchmann P, Schomaecker K, Fischer T,
Eschner W, Hansen H, Morschhauser F, Schicha H, et al: Treatment of
refractory Hodgkin’s lymphoma patients with an iodine-131-labeled
murine anti-CD30 monoclonal antibody. J Clin Oncol 2005, 23:4669-4678.
24. Zhou M, Fadlelmola FM, Cohn JB, Skinnider B, Gascoyne RD, Banerjee D:
Constitutive overexpression of a novel 21 kDa protein by Hodgkin
lymphoma and aggressive non-Hodgkin lymphomas. Mol Cancer 2008,
7:12.
25. Fadlelmola FM, Zhou M, de Leeuw RJ, Dosanjh NS, Harmer K, Huntsman D,
Lam WL, Banerjee D: Sub-megabase resolution tiling (SMRT) array-based
comparative genomic hybridization profiling reveals novel gains and
losses of chromosomal regions in Hodgkin Lymphoma and Anaplastic
Large Cell Lymphoma cell lines. Mol Cancer 2008, 7:2.
26. van der Oord JJ, de Wolf-Peeters C, de Vos R, Desmet VJ: The paracortical
area in dermatopathic lymphadenitis and other reactive conditions of
the lymph node. Virchows Arch B Cell Pathol Incl Mol Pathol 1984,
45:289-299.
27. Soucy P, Luu-The V: Assessment of the ability of type 2 cytochrome b5
to modulate 17,20-lyase activity of human P450c17. J Steroid Biochem
Mol Biol 2002, 80:71-75.
28. Novoradovskaya N, Whitfield ML, Basehore LS, Novoradovsky A, Pesich R,
Usary J, Karaca M, Wong WK, Aprelikova O, Fero M, et al: Universal
Reference RNA as a standard for microarray experiments. BMC Genomics
2004, 5:20.
29. Sültmann H, Kuner R: Universal Human Reference RNA (Stratagene): Cat
Nr: 740000. 2003http://www.stratagene.com/manuals/740000.pdf.
30. Oki Y, Pro B, Fayad LE, Romaguera J, Samaniego F, Hagemeister F,
Neelapu S, McLaughlin P, Goy A, Younes A: Phase 2 study of gemcitabine
in combination with rituximab in patients with recurrent or refractory
Hodgkin lymphoma. Cancer 2008, 112:831-836.
31. Younes A, Consoli U, Snell V, Clodi K, Kliche KO, Palmer JL, Gruss HJ,
Armitage R, Thomas EK, Cabanillas F, Andreeff M: CD30 ligand in
lymphoma patients with CD30+ tumors. J Clin Oncol 1997, 15:3355-3362.
32. Cahill MA: Progesterone receptor membrane component 1: an
integrative review. J Steroid Biochem Mol Biol 2007, 105:16-36.
33. Kimura I, Nakayama Y, Yamauchi H, Konishi M, Miyake A, Mori M, Ohta M,
Itoh N, Fujimoto M: Neurotrophic activity of neudesin, a novel
extracellular heme-binding protein, is dependent on the binding of
heme to its cytochrome b5-like heme/steroid-binding domain. J Biol
Chem 2008, 283:4323-4331.
34. Losel R, Breiter S, Seyfert M, Wehling M, Falkenstein E: Classic and non-
classic progesterone receptors are both expressed in human
spermatozoa. Horm Metab Res 2005, 37:10-14.
35. Mifsud W, Bateman A: Membrane-bound progesterone receptors contain
a cytochrome b5-like ligand-binding domain. Genome Biol 2002, 3:
RESEARCH0068.
36. Pedrazzini E, Villa A, Borgese N: A mutant cytochrome b5 with a
lengthened membrane anchor escapes from the endoplasmic reticulum
and reaches the plasma membrane. Proc Natl Acad Sci USA 1996,
93:4207-4212.
37. Honsho M, Mitoma JY, Ito A: Retention of cytochrome b5 in the
endoplasmic reticulum is transmembrane and luminal domain-
dependent. J Biol Chem 1998, 273:20860-20866.
38. Bulbarelli A, Sprocati T, Barberi M, Pedrazzini E, Borgese N: Trafficking of
tail-anchored proteins: transport from the endoplasmic reticulum to the
plasma membrane and sorting between surface domains in polarised
epithelial cells. J Cell Sci 2002, 115:1689-1702.
39. Ceppi P, Colombo S, Francolini M, Raimondo F, Borgese N, Masserini M:
Two tail-anchored protein variants, differing in transmembrane domain
length and intracellular sorting, interact differently with lipids. Proc Natl
Acad Sci USA 2005, 102:16269-16274.
40. Abell BM, Rabu C, Leznicki P, Young JC, High S: Post-translational
integration of tail-anchored proteins is facilitated by defined molecular
chaperones. J Cell Sci 2007, 120:1743-1751.
41. Rabu C, Wipf P, Brodsky JL, High S: A precursor-specific role for Hsp40/
Hsc70 during tail-anchored protein integration at the endoplasmic
reticulum. J Biol Chem 2008, 283:27504-27513.
42. O’Farrell PH: High resolution two-dimensional electrophoresis of proteins.
J Biol Chem 1975, 250:4007-4021.
43. Bussow K, Cahill D, Nietfeld W, Bancroft D, Scherzinger E, Lehrach H,
Walter G: A method for global protein expression and antibody
screening on high-density filters of an arrayed cDNA library. Nucleic Acids
Research 1998, 26:5007-5008.
Murphy et al. Molecular Cancer 2010, 9:14
http://www.molecular-cancer.com/content/9/1/14
Page 18 of 1944. Horn S, Lueking A, Murphy D, Staudt A, Gutjahr C, Schulte K, Konig A,
Landsberger M, Lehrach H, Felix SB, Cahill DJ: Profiling humoral
autoimmune repertoire of dilated cardiomyopathy (DCM) patients and
development of a disease-associated protein chip. Proteomics 2006,
6:605-613.
45. Lueking A, Horn M, Eickhoff H, Bussow K, Lehrach H, Walter G: Protein
microarrays for gene expression and antibody screening. Anal Biochem
1999, 270:103-111.
46. Chi B, DeLeeuw RJ, Coe BP, MacAulay C, Lam WL: SeeGH–a software tool
for visualization of whole genome array comparative genomic
hybridization data. BMC Bioinformatics 2004, 5:13.
47. de Leeuw RJ, Davies JJ, Rosenwald A, Bebb G, Gascoyne RD, Dyer MJ,
Staudt LM, Martinez-Climent JA, Lam WL: Comprehensive whole genome
array CGH profiling of mantle cell lymphoma model genomes. Hum Mol
Genet 2004, 13:1827-1837.
48. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U,
Speed TP: Exploration, normalization, and summaries of high density
oligonucleotide array probe level data. Biostatistics 2003, 4:249-264.
doi:10.1186/1476-4598-9-14
Cite this article as: Murphy et al.: Constitutively overexpressed 21 kDa
protein in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas
identified as cytochrome B5b (CYB5B). Molecular Cancer 2010 9:14.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Murphy et al. Molecular Cancer 2010, 9:14
http://www.molecular-cancer.com/content/9/1/14
Page 19 of 19